



## AddLife publishes prospectus regarding the rights issue

The prospectus regarding the rights issue in AddLife AB (publ), reg. no. 556995-8126 ("AddLife"), has been approved and registered by the Swedish Financial Supervisory Authority and is now available at AddLifes website, [www.add.life](http://www.add.life), and at Handelsbankens website for investment offers, [www.handelsbanken.se/investeringserbjudande](http://www.handelsbanken.se/investeringserbjudande). The prospectus will also, in a few days, be made available at the Swedish Financial Supervisory Authority's website [www.fi.se](http://www.fi.se).

Please find the prospectus at [www.add.life/en/investors/financial-reports-and-presentations/preferential-rights-issue-2019](http://www.add.life/en/investors/financial-reports-and-presentations/preferential-rights-issue-2019) or [www.handelsbanken.se/investeringserbjudande](http://www.handelsbanken.se/investeringserbjudande). The prospectus can also be ordered from AddLife by e-mail: [info@add.life](mailto:info@add.life), or by telephone: +46 (0)8-420 03 830.

### Adviser

Handelsbanken Capital Markets is financial adviser in connection with the rights issue. Advokatfirman Delphi is legal adviser.

Stockholm, 28 January 2019  
AddLife AB (publ)

### For further information, please contact:

Kristina Willgård, CEO, [kristina.willgard@add.life](mailto:kristina.willgard@add.life), +46 (0)705 10 12 23  
Martin Almgren, CFO, [martin.almgren@add.life](mailto:martin.almgren@add.life), +46 (0)702 28 15 45

### IMPORTANT INFORMATION

The information in this press release shall not constitute an offer to acquire, subscribe for or otherwise trade in shares or other securities in AddLife. No action has been taken and measures will not be taken to permit an offer to the public in any jurisdictions other than Sweden.

The information in this press release may not be released, published or distributed, directly or indirectly, in or into the United States (including its territories and provinces, every state in the United States and the District of Columbia (the "US"), Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore or South Africa or at any other person where participation would require an additional prospectus, registration or other measures than those that follow by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws.

No action has been taken or will be taken by AddLife that would permit an offer to the public in any country other than Sweden. Neither subscription rights in the offer, paid and subscribed shares nor new shares subscribed for in the offer have been, or will be, registered under the United States Securities Act of 1933 as amended (the "Securities Act"). Securities may not be offered or sold, directly or indirectly, in or into the US, or to persons domiciled there, except pursuant to an applicable exemption from the registration requirements of the Securities Act.

*AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sector, mainly in the Nordic region. AddLife has about 900 employees in some 40 operating subsidiaries. The group currently has net sales of around SEK 2.5 billion. The AddLife share is listed on Nasdaq Stockholm.*

*This information is information that AddLife AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons set out above, on 28 January 2019 at 16.30 (CET).*